Super-Rehab: Can we Achieve Coronary Artery Disease Regression?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-01

Study Completion Date

2023-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Super Rehab: Can we Achieve Coronary Artery Disease Regression? (a feasibility study) proposes to test the use of a novel lifestyle intervention (Super Rehab), in addition to standard care, for patients with both coronary artery disease and metabolic syndrome. This is a feasibility study that will test study processes, enable optimisation of the intervention and provide data for power calculations to enable design of pivotal trials of the clinical effectiveness of Super Rehab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Wearable Technology for Personalised Physical Activity Feedback in Cardiac Patients: a Feasibility Study

NCT05605015

Cardiovascular Diseases

COMPLETED EARLY_PHASE1

Assessing the Feasibility of Including Patients With Peripheral Artery Disease in to an Established Cardiac Rehabilitation Service.

NCT03564080

Peripheral Arterial Disease Cardiovascular Diseases Intermittent Claudication +1 more

COMPLETED NA

Cardiac Rehabilitation for the Treatment of Refractory Angina

NCT00411359

Angina Pectoris Coronary Disease

COMPLETED PHASE3

Optimising Secondary Prevention and Quality of Life in Early Cardiac Rehabilitation

NCT04781699

Cardiovascular Diseases Coronary Artery Disease Myocardial Infarction +3 more

UNKNOWN

Self-management and Theory-based Rehabilitation Encouraging New Gateways to Healthy-Hearts

NCT05705310

Coronary Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this research we will study the feasibility of a randomised controlled trial (RCT) of a novel lifestyle intervention (Super Rehab), in addition to usual care, for patients with established coronary artery disease (CAD) and metabolic syndrome. Increasing evidence has shown that CAD can not only be stabilised, but can in fact regress with treatments that include lifestyle interventions.

This feasibility study will involve patients undergoing a clinically indicated coronary CT angiography (CCTA) scan who are found to have confirmed CAD with plaque causing a narrowing in at least one coronary artery of ≥25% of the lumen on their CTCA; have evidence of coronary inflammation (defined by an abnormal fat attenuation index (FAI) of \> -70.1HU or with FAI score \[relative to age and sex matched patients\] ≥ 75th percentile in the left anterior coronary or right coronary artery or with FAI score ≥ 90th percentile in the circumflex coronary); have Metabolic Syndrome, defined as any 3 of: high abdominal waist circumference (≥94cm males, ≥80cm females), hypertension (≥130/85mmHg or on treatment), raised fasting glucose (≥5.6mmol/L or on diabetic treatment), low HDL (≤1mmol/L males, \<1.3mmol/L females), and high triglycerides (\>1.7mmol/L).

Participants will be randomised to either Super Rehab and Usual Care or to continue Usual Care only. Super Rehab includes a combination of separate 1:1 supervised high-intensity exercise and dietary advice sessions, and the whole programme lasts 12 months. Participants in both arms will undergo imaging, fitness, clinical tests (including blood tests), and complete questionnaires on four occasions during the study, alongside short interim and detailed end-of-study interviews.

The study will primarily assess key feasibility outcomes to guide a potential subsequent RCT, e.g. recruitment and retention rates and test the acceptability of the intervention and study processes. In addition, the study will provide baseline data for power calculations to support study design for the planned future RCT into the clinical effectiveness of Super Rehab in this patient group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients randomized to Usual Care or Super Rehab plus Usual Care

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

Patients will continue Usual Care, which will include aspirin, a statin and routine lifestyle advice

Group Type NO_INTERVENTION

No interventions assigned to this group

Super Rehab plus Usual Care

12-month Super Rehab programme plus Usual Care

Group Type EXPERIMENTAL

Super Rehab

Intervention Type BEHAVIORAL

A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Super Rehab

A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. CCTA demonstrating coronary artery disease with plaque causing a narrowing in at least one coronary artery of ≥ 25% stenosis and a evidence of coronary inflammation (defined by an abnormal fat attenuation index (FAI; defined as FAI \> -70.1HU or with FAI score \[relative to age and sex matched patients\] ≥ 75th percentile in the left anterior coronary or right coronary artery or with FAI score ≥ 90th percentile in the circumflex coronary)
2. Have Metabolic Syndrome, defined as any 3 of: high abdominal waist circumference (≥94cm males, ≥80cm females), hypertension (≥130/85mmHg or on treatment), raised fasting glucose (≥5.6mmol/L or on diabetic treatment), low HDL (≤1mmol/L males, \<1.3mmol/L females), and high triglycerides (\>1.7mmol/L).

Exclusion Criteria

1. Coronary artery disease requiring revascularisation
2. Unstable angina
3. New York Heart Association class III/IV heart failure or severe left ventricular impairment
4. Severe valve disease
5. Significant cardiomyopathy (as assessed by screening Cardiologist)
6. Severe hypertension (defined as blood pressure \>180/120mmHg)
7. Uncontrolled cardiac arrhythmia
8. Previous aortic dissection
9. Recent acute pulmonary embolus deep vein thrombosis, stroke or transient ischaemic attack
10. Severe autonomic or peripheral neuropathy
11. Acute systemic illness or fever
12. Significant acute or chronic renal failure
13. Pulmonary fibrosis or interstitial lung disease
14. Physically unable to participate in exercise
15. Previous myocardial infarction or coronary re-vascularisation
16. Severe coronary calcification that precludes assessment of the coronary lumen on CCTA
17. A clinically significant ECG abnormality at the screening visit, which in the opinion of the screening Cardiologist exposes the subject to risk by enrolling in the trial
18. Pregnant or breastfeeding
19. Current participation in another intervention based research study
20. Inability to fully understand the verbal and written descriptions of the study and the instructions provided during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No